文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

In-situ-formed TCM-inspired dual-function nanocomposite hydrogel for intraoperative hemostasis and postoperative recurrence prevention in hepatocellular carcinoma.

作者信息

Lu Huiwen, Li Yucong, Chen Jingle, Song Da, Luo Xiaoqi, Lu Xinhao, Huang Xuhui, Tan Wei, Xie Chao, Wang Changjun

机构信息

Department of Traditional Chinese Medicine, Guangdong Geriatric Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, PR China.

Department of Joint and Orthopedics, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, PR China.

出版信息

Mater Today Bio. 2025 Aug 13;34:102192. doi: 10.1016/j.mtbio.2025.102192. eCollection 2025 Oct.


DOI:10.1016/j.mtbio.2025.102192
PMID:40893360
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12390958/
Abstract

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, with high postoperative recurrence rates due to occult micrometastases or minimal residual disease, markedly worsening the prognosis for HCC patients. Current therapies lack effective strategies to prevent recurrence, while traditional Chinese medicine (TCM) shows potential in delaying HCC progression. Combining a hemostatic hydrogel with nanoparticle-based delivery of active TCM components provides a strategy to enhance tumor recurrence prevention. Herein, we develop a nanocomposite hydrogel (HPS@ZCJ) by encapsulating Jianpi-Huayu essential oils (JEO) into zein-based nanoparticles (zein@chondroitin sulfate@JEO, ZCJ) and embedding them in a hydroxymethyl cellulose/Pluronic F-127/sodium alginate (HPS) hydrogel matrix. HPS@ZCJ hydrogel enhances cytotoxic T-lymphocyte infiltration, inhibits the polarization of tumor-associated macrophages to M2 phenotype, induces tumor cell death, reverses immunosuppression, and inhibits angiogenesis within the tumor. The antitumor mechanism involves dual downregulation of GPNMB and DHCR7, key genes in HCC progression and immune evasion. In and in experiments demonstrate that HPS@ZCJ hydrogel-mediated targeted comprehensive therapy simultaneously achieves intraoperative hemostasis, impedes primary tumor growth and prevents HCC postoperative recurrence. This study provides a promising postoperative HCC treatment strategy, leveraging TCM's therapeutic potential with significant clinical translation prospects.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c90/12390958/87b2a7116d09/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c90/12390958/f2839c3cf995/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c90/12390958/7186adcbea43/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c90/12390958/224cf2af09b5/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c90/12390958/910c91a3cf62/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c90/12390958/7da36d0b9b2a/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c90/12390958/aba2b7fe915e/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c90/12390958/e59852ac3b54/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c90/12390958/87b2a7116d09/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c90/12390958/f2839c3cf995/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c90/12390958/7186adcbea43/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c90/12390958/224cf2af09b5/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c90/12390958/910c91a3cf62/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c90/12390958/7da36d0b9b2a/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c90/12390958/aba2b7fe915e/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c90/12390958/e59852ac3b54/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c90/12390958/87b2a7116d09/gr8.jpg

相似文献

[1]
In-situ-formed TCM-inspired dual-function nanocomposite hydrogel for intraoperative hemostasis and postoperative recurrence prevention in hepatocellular carcinoma.

Mater Today Bio. 2025-8-13

[2]
ZBED4: A Prognostic Biomarker and Therapeutic Target in Hepatocellular Carcinoma.

J Hepatocell Carcinoma. 2025-8-21

[3]
Resveratrol suppresses liver cancer progression by downregulating AKR1C3: targeting HCC with HSA nanomaterial as a carrier to enhance therapeutic efficacy.

Apoptosis. 2024-10

[4]
Prescription of Controlled Substances: Benefits and Risks

2025-1

[5]
DS-Modified Paeoniflorin pH-Responsive Lipid-Polymer Hybrid Nanoparticles for Targeted Macrophage Polarization in a Rat Model of Rheumatoid Arthritis.

Int J Nanomedicine. 2025-7-12

[6]
Integrated network pharmacology and experimental validation reveal EGFR/p53/Bcl-2-mediated anti-hepatocellular carcinoma effects of Zedoary Turmeric Oil.

J Ethnopharmacol. 2025-7-3

[7]
Chinese medicines as therapeutic options for treating prostate cancer: Therapeutic effects and underlying mechanisms.

J Ethnopharmacol. 2025-8-27

[8]
Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma.

Cochrane Database Syst Rev. 2015-1-26

[9]
Harnessing multi-omics and artificial intelligence: revolutionizing prognosis and treatment in hepatocellular carcinoma.

Front Immunol. 2025-7-23

[10]
Controlled Delivery of C-C Motif Chemokine Ligand 25 by a Hydrogel for Tumor Microenvironment Remodeling in Triple Negative Breast Cancer.

Acta Biomater. 2025-7-23

本文引用的文献

[1]
Ropivacaine and celecoxib-loaded injectable composite hydrogel for improved chronic pain-exacerbated myocardial ischemia-reperfusion injury.

J Control Release. 2025-3-10

[2]
Effects of Jianpi Huayu Decoction on Th1/Th2 Immune Balance in Mice With Liver Cancer-Related Fatigue via the IL- 27/STAT1 Signaling Pathway.

Integr Cancer Ther. 2024

[3]
In-situ-formed immunotherapeutic and hemostatic dual drug-loaded nanohydrogel for preventing postoperative recurrence of hepatocellular carcinoma.

J Control Release. 2024-8

[4]
Targeting the oncogenic m6A demethylase FTO suppresses tumourigenesis and potentiates immune response in hepatocellular carcinoma.

Gut. 2024-12-10

[5]
Injectable and self-healable nano-architectured hydrogel for NIR-light responsive chemo- and photothermal bacterial eradication.

J Mater Chem B. 2024-2-14

[6]
Dehydrocostus lactone suppresses gastric cancer progression by targeting ACLY to inhibit fatty acid synthesis and autophagic flux.

J Adv Res. 2025-1

[7]
A hemostatic sponge derived from chitosan and hydroxypropylmethylcellulose.

J Mech Behav Biomed Mater. 2024-2

[8]
Biomimetic and bioinspired nano-platforms for cancer vaccine development.

Exploration (Beijing). 2023-4-25

[9]
Gel/hydrogel-based in situ biomaterial platforms for cancer postoperative treatment and recovery.

Exploration (Beijing). 2023-5-31

[10]
TMEM147 aggravates the progression of HCC by modulating cholesterol homeostasis, suppressing ferroptosis, and promoting the M2 polarization of tumor-associated macrophages.

J Exp Clin Cancer Res. 2023-10-28

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索